Osteoporosis Practice Bulletin

Publication Date: September 1, 2012
Last Updated: March 14, 2022

Recommendations and Conclusions

The following recommendations and are based on good and consistent scientific evidence.

  • Treatment should be recommended for:
    • Women with a T-score of –2.5 or less
    • Women who have had low-trauma fracture
    • Women who have a T-score from –1 to –2.5 and a FRAX score greater than or equal to 3% for risk of hip fracture or a FRAX score greater than or equal to 20% for risk of a major osteoporotic fracture (defined as forearm, hip, shoulder, or clinical spine fracture) or both in the next 10 years
  • FDA-approved therapies should be used for medical treatment: raloxifene, bisphosphonates, PTH, denosumab, calcitonin.
  • Bone density screening for women should begin at age 65 years. Dual-energy X-ray absorptiometry screening can be used selectively for women younger than 65 years if they are postmenopausal and have other significant risk factors for osteoporosis or fracture.



Osteoporosis Practice Bulletin

Authoring Organization